SOFTSERVE
6.5.2021 13:02:12 CEST | Business Wire | Press release
SoftServe’s corporate charity fund, “Open Eyes ” has opened a “Positive Room ” for patients of the Dnipro Regional Children’s Clinical Hospital. The Positive Room in Dnipro, the sixth such space in Ukraine, was opened at the Department of Reconstructive Surgery thanks to charitable donations by SoftServe, its employees, and other contributors. The Department helps as many as 30 children at a time recover from the most serious, life-threatening illnesses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210506005004/en/
“We treat children with the most serious diseases: congenital malformations, chemical burns of the esophagus, disorders of the gastrointestinal tract, and tumors requiring surgery,” said Oleksandr Gladkyi, head of the Department of Reconstructive Surgery of Dnipro Regional Children's Clinical Hospital. “The room is a kind of island in their hospital routine, where children can spend quality time with animators and volunteers, who help take their minds off illness."
“Children from birth to age 18 are treated here,” said Yuliia Lozinska, Director of SoftServe’s Dnipro office. “Each of them spends from several weeks to months on end at this hospital. This is a time when they can study, play, and make new friends with their peers. That is why we have created a comfortable space within the hospital that will provide children with opportunities for recreation, entertainment, and study.”
Children who have been undergoing lengthy treatments are missing out on kindergarten or school. These young patients miss opportunities to communicate and play with peers, thus affecting their socialization. To address this, SoftServe’s Open Eyes team set out on a mission to create zones dedicated to children's education and recreation.
According to Roman Perepichka, project coordinator at the charity fund, the design and functionality of the room were the result of cooperation between doctors from many departments and two designers, Alyona Chursynova and Mariia Melets, who specialize in designing inclusive spaces at hospitals. Young patients can now use the room as their space for play and study. Teachers come to teach various classes and have workshops, which were some of the main goals behind creating the Positive Room.
The Positive Rooms project started in October 2017. It was then that the Fund opened the first Positive Room space in Poland at the Wrocław Children's Clinic of Endocrinology and Diabetology in partnership with the Pozytywne.com Association. After successful completion, the decision was made to implement a similar project in Ukraine. The spaces vary in size depending on the provisions of a particular institution, and each features zoning created in cooperation with designers, doctors, teachers, psychologists, and other professionals.
The Open Eyes Charity Fund is currently raising donations through a fundraising platform to open another Positive Room in Lviv. Fundraising also began in 2021 to fund two more Positive Rooms in Kyiv and Chernivtsi.
About Open Eyes Charity Fund
SoftServe founded the Open Eyes Charity Fund in 2014. Initially, the Fund served as an internal platform to help raise funds and assist SoftServe’s associates in implementing charitable projects that they would also join as volunteers. In 2017, the fundraising platform at www.openeyes.org.ua was opened to external donors. Since then, both SoftServe’s associates and anyone interested have had the opportunity to support the Fund's charitable initiatives.
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation, from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website , blog , LinkedIn , Facebook , and Twitter pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005004/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
Andersen Consulting får ny samarbejdspartner i Usbekistan22.10.2026 21:34:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for cybersikkerhed og forretningstransformation gennem en samarbejdsaftale med Algoruni, et konsulentfirma med base i Usbekistan. Algoruni rådgiver organisationer om at opbygge cyberrobusthed og håndtere bredere prioriteter inden for ledelse, regulering og bæredygtighed. Virksomheden har base i Tasjkent og tilbyder tjenester inden for cybersikkerhedsstrategi og databeskyttelse, virksomhedsledelse og driftsforbedringer samt ESG-strategi og -rapportering. Fokus er på praktiske løsninger, der er tilpasset den enkelte kundes situation. "Enhver organisation står over for en unik kombination af risici og muligheder. Derfor mener vi, at effektive løsninger skal tage udgangspunkt i virksomhedens konkrete situation," udtalte Alisher Zaynutdinov, administrerende direktør for Algoruni. "Som samarbejdsvirksomhed med Andersen Consulting kan vi kombinere denne tilgang med et bredere netværk af internationale ressourcer og perspektiver, så vi får nye
Andersen Global udvider sine juridiske kompetencer i Argentina gennem samarbejde med MHR22.10.2026 20:20:00 CEST | Pressemeddelelse
Andersen Global styrker sine juridiske kompetencer i Argentina gennem en samarbejdsaftale med Martínez de Hoz & Rueda (MHR) efter integrationen af teamet fra MBP Partners i firmaet. MBP Partners var tidligere et samarbejdsfirma i Andersen Global og arbejdede sammen med organisationens medlemsfirmaer og samarbejdsfirmaer for at bistå klienter med både lokale og internationale forhold. Med integrationen af MBP Partners viderefører den nye samarbejdsaftale mellem Andersen Global og MHR det eksisterende samarbejde og styrker samtidig Andersen Globals juridiske kompetencer i Argentina. MHR er et fullservice advokatfirma, der rådgiver klienter inden for olie og gas, selskabsretlige og finansielle forhold, energi, minedrift, fintech, infrastruktur, teknologi og andre centrale sektorer. Firmaet bistår danske og internationale virksomheder, finansielle institutioner, investeringsfonde, fintechvirksomheder og andre organisationer med komplekse transaktioner, regulatoriske spørgsmål og strategisk
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press release
For Trade and Medical Media Only Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
